person · Reporting owner
ANDREWS RONALD ASBURY
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CERENOME, INC.CNSY · Entity 7637 | Director | October 01, 2026 | October 01, 2026 |
| Insight Molecular Diagnostics Inc.OCX · Entity 6631 | Director · Former CEO | December 01, 2022 | December 10, 2022 |
| Precipio, Inc.PRPO · Entity 7207 | Director | October 15, 2025 | January 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CERENOME, INC.
Report date October 01, 2026 · Filed October 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,843 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Exercise / conversion · Acquired 921 · Balance 1,843 F2: Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments beginning on July 1, 2026. F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 1,843 |
Reported balance
After 2026-10-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-01 · Exercise / conversion · Disposed 921 · Balance 1,843 F2: Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments beginning on July 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock.
F2: Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments beginning on July 1, 2026.
Insight Molecular Diagnostics Inc.
Report date December 01, 2022 · Filed December 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, no par valueSEC Table I · non-derivative | Direct | 583,212 |
Reported balance
After 2022-12-01 transaction · row 1
1 source rowRow 1 · 2022-12-01 · Exercise / conversion · Acquired 250,000 · Balance 583,212 |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.10 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-12-01 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining options immediately vested and became exercisable as of December 1, 2022. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.40 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-12-01 · Disposition to issuer · Disposed 45,000 · Balance 0 F1: The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining options immediately vested and became exercisable as of December 1, 2022. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.51 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-12-01 · Disposition to issuer · Disposed 950,000 · Balance 0 F1: The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining options immediately vested and became exercisable as of December 1, 2022. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.68 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-12-01 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining options immediately vested and became exercisable as of December 1, 2022. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $5.34 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-12-01 · Disposition to issuer · Disposed 500,000 · Balance 0 F1: The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining options immediately vested and became exercisable as of December 1, 2022. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.15 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-12-01 · Disposition to issuer · Disposed 300,000 · Balance 0 F1: The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining options immediately vested and became exercisable as of December 1, 2022. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.15 | Direct | 281,250 |
Reported balance
After 2022-12-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-12-01 · Disposition to issuer · Disposed 93,750 · Balance 281,250 F1: The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining options immediately vested and became exercisable as of December 1, 2022. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.46 · Expires 2032-12-07 | Direct | 50,000 |
Reported balance
After 2022-12-07 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2022-12-07 · Grant · Acquired 50,000 · Balance 50,000 F3: Options vest (and thereby become exercisable) as follows: (i) one-third on December 31, 2022, (ii) one-third on January 31, 2023, and (iii) one-third on February 28, 2023 (each such date, a "Vesting Date"), in each case, subject to the Reporting Person's continuous service as a consultant on each applicable Vesting Date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-12-01 · Disposition to issuer · Disposed 35,000 · Balance 0 F2: The restricted stock units were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining restricted stock units immediately vested on December 1, 2022. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 250,000 |
Reported balance
After 2022-12-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-12-01 · Disposition to issuer · Disposed 250,000 · Balance 250,000 F2: The restricted stock units were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining restricted stock units immediately vested on December 1, 2022. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-12-01 · Exercise / conversion · Disposed 250,000 · Balance 0 F2: The restricted stock units were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining restricted stock units immediately vested on December 1, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining options immediately vested and became exercisable as of December 1, 2022.
F2: The restricted stock units were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining restricted stock units immediately vested on December 1, 2022.
F3: Options vest (and thereby become exercisable) as follows: (i) one-third on December 31, 2022, (ii) one-third on January 31, 2023, and (iii) one-third on February 28, 2023 (each such date, a "Vesting Date"), in each case, subject to the Reporting Person's continuous service as a consultant on each applicable Vesting Date.
Precipio, Inc.
Report date October 15, 2025 · Filed January 20, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,796 |
Reported balance
After 2025-10-15 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2025-10-15 · Grant · Acquired 568 · Balance 15,796 F1: This Form 4/A is being filed to correct the reporting person's aggregate beneficial ownership, which was understated by 88 shares in the original Form 4 filed on October 15, 2025 due to an administrative reporting error. No additional transactions occurred other than those previously reported. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4/A is being filed to correct the reporting person's aggregate beneficial ownership, which was understated by 88 shares in the original Form 4 filed on October 15, 2025 due to an administrative reporting error. No additional transactions occurred other than those previously reported.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Oxford Immunotec Global PLC
Report date March 08, 2021 · Filed March 12, 2021
Section 16 reporting ended · disclosed 2021-03-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 1
1 source rowRow 1 · 2021-03-08 · Disposition to issuer · Disposed 4,081 · Balance 0 F1: Disposed pursuant to the acquisition by PerkinElmer (UK) Holdings Limited of the entire issued share capital of Oxford Immunotec Global PLC on March 8, 2021 by means of a scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.65 · Expires 2026-06-28 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.46 · Expires 2027-06-06 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.49 · Expires 2028-06-19 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.44 · Expires 2029-06-18 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.50 · Expires 2025-11-04 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-03-08 · Disposition to issuer · Disposed 14,914 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.50 · Expires 2025-11-04 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.96 · Expires 2030-06-24 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-03-08 · Disposition to issuer · Disposed 9,494 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed pursuant to the acquisition by PerkinElmer (UK) Holdings Limited of the entire issued share capital of Oxford Immunotec Global PLC on March 8, 2021 by means of a scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme").
F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price.
F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 1, 2026 16:00 UTC | CERENOME, INC. CNSY · Entity 7637 | Exercise / conversionRestricted Stock Units · Derivative | 921 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-409861 · ownership.xml · derivative · entry 2 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,843 Underlying: Common Stock · 921 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments beginning on July 1, 2026. F2 · derivative.expiration_date: Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments beginning on July 1, 2026. Read SEC document |
| October 01, 2026 Filed Oct 1, 2026 16:00 UTC | CERENOME, INC. CNSY · Entity 7637 | Exercise / conversionCommon Stock | 921 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-409861 · ownership.xml · nonDerivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,843 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments beginning on July 1, 2026. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock. Read SEC document |
| July 01, 2026 Filed Jul 1, 2026 20:30 UTC | CERENOME, INC. PSTV · Entity 7637 | Exercise / conversionRestricted Stock Units · Derivative | 922 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-292654 · ownership.xml · derivative · entry 2 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,764 Underlying: Common Stock · 922 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments beginning on July 1, 2026. F2 · derivative.expiration_date: Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments beginning on July 1, 2026. Read SEC document |
| July 01, 2026 Filed Jul 1, 2026 20:30 UTC | CERENOME, INC. PSTV · Entity 7637 | Exercise / conversionCommon Stock | 922 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-292654 · ownership.xml · nonDerivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 922 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments beginning on July 1, 2026. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:10 UTC | CERENOME, INC. PSTV · Entity 7637 | GrantStock Option (Right to Buy) · Derivative | 1,600 | $0.00 Strike: $5.76 | $0.00 |
DisclosureSEC source: 0001193125-26-228922 · ownership.xml · derivative · entry 3 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,600 Underlying: Common Stock · 1,600 shares Expires 2036-05-14 F3 · derivative.exercise_date: The options vest monthly over 24 months from the grant date in substantially equaly monthly increments. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:10 UTC | CERENOME, INC. PSTV · Entity 7637 | GrantStock Option (Right to Buy) · Derivative | 3,686 | $0.00 Strike: $5.76 | $0.00 |
DisclosureSEC source: 0001193125-26-228922 · ownership.xml · derivative · entry 2 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,686 Underlying: Common Stock · 3,686 shares Expires 2036-05-14 F2 · derivative.exercise_date: The options vest monthly over 12 months from the grant date in substantially equal monthly increments, provided that the options vest in full on the Issuer's 2027 Annual Stockholder Meeting, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date or, if earlier, such annual meeting. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:10 UTC | CERENOME, INC. PSTV · Entity 7637 | GrantRestricted Stock Units · Derivative | 3,686 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-228922 · ownership.xml · derivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,686 Underlying: Common Stock · 3,686 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs awarded vest ratably over four quarters in substantially equal 1/4th increments, commencing with 1/4th vesting on July 1, 2026 and the remainder vesting quarterly thereafter. F1 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs awarded vest ratably over four quarters in substantially equal 1/4th increments, commencing with 1/4th vesting on July 1, 2026 and the remainder vesting quarterly thereafter. F1 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs awarded vest ratably over four quarters in substantially equal 1/4th increments, commencing with 1/4th vesting on July 1, 2026 and the remainder vesting quarterly thereafter. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:30 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $23.82 | $0.00 |
DisclosureSEC source: 0001104659-26-001334 · tm261953-1_4seq1.xml · derivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2036-01-02 F2 · price: The stock option was granted pursuant to the Issuer's Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer and has an exercise price of $23.82 per share. F1 · derivative.exercise_date: The options shall vest in twelve equal monthly installments beginning on the one-month anniversary of the date of the issuance. Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 20:30 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantCommon Stock | 568 | $17.58 | $9,985.44 |
DisclosureSEC source: 0001104659-25-100104 · tm2528907-1_4seq1.xml · nonDerivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,708 F1 · shares: 568 shares of common stock were granted upon the close of business on October 15, 2025, as a consideration in lieu of cash payment of compensation for service as a member of the Board of Directors for Q3-25. Read SEC document |
| October 15, 2025 Filed Jan 20, 2026 21:25 UTC Amendment | Precipio, Inc. PRPO · Entity 7207 | GrantCommon Stock | 568 | $17.58 | $9,985.44 |
DisclosureSEC source: 0001104659-26-005081 · tm263642-10_4aseq1.xml · nonDerivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,796 F1 · price: This Form 4/A is being filed to correct the reporting person's aggregate beneficial ownership, which was understated by 88 shares in the original Form 4 filed on October 15, 2025 due to an administrative reporting error. No additional transactions occurred other than those previously reported. F1 · balance_after: This Form 4/A is being filed to correct the reporting person's aggregate beneficial ownership, which was understated by 88 shares in the original Form 4 filed on October 15, 2025 due to an administrative reporting error. No additional transactions occurred other than those previously reported. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 20:36 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantCommon Stock | 676 | $14.78 | $9,991.28 |
DisclosureSEC source: 0001104659-25-069057 · tm2521234-3_4seq1.xml · nonDerivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,228 F1 · shares: 676 shares of common stock were granted upon the close of business on July 16, 2025, as a consideration in lieu of cash payment of compensation for service as a member of the Board of Directors for Q2-25. Read SEC document |
| April 15, 2025 Filed Apr 17, 2025 21:02 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantCommon Stock | 1,785 | $5.60 | $9,996.00 |
DisclosureSEC source: 0001104659-25-036085 · tm2512512-3_4seq1.xml · nonDerivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,552 F1 · shares: 1,785 shares of common stock were granted upon the close of business on April 15, 2025, as a consideration in lieu of cash payment of compensation for service as a member of the Board of Directors for Q1-25. Read SEC document |
| January 15, 2025 Filed Jan 16, 2025 22:15 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantCommon Stock | 1,639 | $6.10 | $9,997.90 |
DisclosureSEC source: 0001104659-25-004156 · tm253548-1_4seq1.xml · nonDerivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,767 F1 · shares: 1,639 shares of common stock were granted upon the close of business on January 15, 2025, as a consideration in lieu of cash payment of compensation for service as a member of the Board of Directors for Q4-24. Read SEC document |
| January 14, 2025 Filed Jan 16, 2025 22:17 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $6.06 | $0.00 |
DisclosureSEC source: 0001104659-25-004164 · tm253548-5_4seq1.xml · derivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2035-01-14 F2 · price: Issued pursuant to the Issuer's Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer. F1 · derivative.exercise_date: The options shall vest in twelve equal monthly installments beginning on the one-month anniversary of the date of the issuance. Read SEC document |
| October 15, 2024 Filed Oct 17, 2024 20:34 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantCommon Stock | 1,510 | $6.62 | $9,996.20 |
DisclosureSEC source: 0001104659-24-109550 · tm2426435d1_4seq1.xml · nonDerivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,128 F1 · price: 1,510s hares of common stock were granted upon the close of business on October 15, 2024, as a consideration in lieu of cash payment of compensation for service as a member of the Board of Directors for Q3-24. Read SEC document |
| August 31, 2024 Filed Sep 6, 2024 21:11 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $6.56 | $0.00 |
DisclosureSEC source: 0001104659-24-097790 · tm2423539-6_4seq1.xml · derivative · entry 8 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2032-01-11 F3 · derivative.exercise_price: The exercise price of the option is $6.56 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service with the Issuer is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F1 · kind: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the "2017 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 31, 2024 Filed Sep 6, 2024 21:11 UTC | Precipio, Inc. PRPO · Entity 7207 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $30.80 | $0.00 |
DisclosureSEC source: 0001104659-24-097790 · tm2423539-6_4seq1.xml · derivative · entry 7 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2032-01-11 F1 · kind: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the "2017 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 31, 2024 Filed Sep 6, 2024 21:11 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 1,250 | $0.00 Strike: $6.56 | $0.00 |
DisclosureSEC source: 0001104659-24-097790 · tm2423539-6_4seq1.xml · derivative · entry 6 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 1,250 shares Expires 2031-03-08 F3 · derivative.exercise_price: The exercise price of the option is $6.56 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service with the Issuer is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F1 · kind: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the "2017 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 31, 2024 Filed Sep 6, 2024 21:11 UTC | Precipio, Inc. PRPO · Entity 7207 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,250 | $0.00 Strike: $64.40 | $0.00 |
DisclosureSEC source: 0001104659-24-097790 · tm2423539-6_4seq1.xml · derivative · entry 5 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires 2031-03-08 F1 · kind: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the "2017 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 31, 2024 Filed Sep 6, 2024 21:11 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 258 | $0.00 Strike: $6.56 | $0.00 |
DisclosureSEC source: 0001104659-24-097790 · tm2423539-6_4seq1.xml · derivative · entry 4 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 258 Underlying: Common Stock · 258 shares Expires 2031-03-01 F3 · derivative.exercise_price: The exercise price of the option is $6.56 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service with the Issuer is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F1 · kind: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the "2017 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 31, 2024 Filed Sep 6, 2024 21:11 UTC | Precipio, Inc. PRPO · Entity 7207 | Disposition to issuerStock Option (Right to Buy) · Derivative | 258 | $0.00 Strike: $52.00 | $0.00 |
DisclosureSEC source: 0001104659-24-097790 · tm2423539-6_4seq1.xml · derivative · entry 3 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 258 shares Expires 2031-03-02 F1 · kind: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the "2017 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 31, 2024 Filed Sep 6, 2024 21:11 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 103 | $0.00 Strike: $6.56 | $0.00 |
DisclosureSEC source: 0001104659-24-097790 · tm2423539-6_4seq1.xml · derivative · entry 2 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103 Underlying: Common Stock · 103 shares Expires 2031-03-01 F3 · derivative.exercise_price: The exercise price of the option is $6.56 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service with the Issuer is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F1 · kind: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the "2017 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 31, 2024 Filed Sep 6, 2024 21:11 UTC | Precipio, Inc. PRPO · Entity 7207 | Disposition to issuerStock Option (Right to Buy) · Derivative | 103 | $0.00 Strike: $52.00 | $0.00 |
DisclosureSEC source: 0001104659-24-097790 · tm2423539-6_4seq1.xml · derivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 103 shares Expires 2031-03-02 F1 · kind: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the "2017 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| July 15, 2024 Filed Jul 16, 2024 20:30 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantCommon Stock | 2,157 | $4.63 | $9,986.91 |
DisclosureSEC source: 0001104659-24-080213 · tm2419567-1_4seq1.xml · nonDerivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,618 F1 · shares: 2,157 shares of common stock were granted upon the close of business on July 15, 2024, as a consideration in lieu of cash payment of compensation for service as a member of the Board of Directors for Q2-24. Read SEC document |
| June 21, 2024 Filed Jun 25, 2024 21:02 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0001104659-24-074788 · tm2418227-1_4seq1.xml · derivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2034-06-21 F2 · price: Issued pursuant to the Issuer's Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer F1 · derivative.exercise_date: The options shall vest in twelve equal monthly installments beginning on the one-month anniversary of the date of the issuance Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 20:21 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantCommon Stock | 3,153 | $6.66 | $20,998.98 |
DisclosureSEC source: 0001104659-24-048320 · tm2412083-2_4seq1.xml · nonDerivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,461 F1 · price: 3,153 shares of common stock were granted upon the close of business on April 15, 2024, as a consideration in lieu of cash payment of deferred compensation for service as a member of the Board of Directors for Q4-23 and Q1-24. The price reported in Column 4 is a weighted average price ranging from $5.35 to $6.74. The reporting person undertakes to provide, upon request, full information regarding the number of shares calculated at each separate price within the range set forth in this footnote. Read SEC document |
| October 24, 2023 Filed Oct 26, 2023 20:30 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantCommon Stock | 4,005 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-111758 · tm2329242-3_4seq1.xml · nonDerivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,308 F1 · price: The 4,005 shares of common stock were granted upon the close of business on October 24, 2023 as consideration in lieu of cash payment of deferred compensation for service as a member of the Board of Directors. Read SEC document |
| September 12, 2023 Filed Sep 14, 2023 20:39 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantCommon Stock | 6,060 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-100810 · tm2326171-1_4seq1.xml · nonDerivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,060 F1 · price: The 6,060 restricted shares of common stock were granted upon the close of business on September 12, 2023 and vested immediately upon issuance. The restricted shares were issued as consideration in lieu of cash payment of deferred compensation for service as a member of the Board of Directors. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 21:42 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 30,000 | Not disclosed Strike: $0.62 | Not disclosed |
DisclosureSEC source: 0001104659-23-002759 · tm233036-1_4seq1.xml · derivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-01-06 F2 · price: Issued pursuant to the Issuer's Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer F1 · derivative.exercise_date: The options shall vest in twelve equal monthly installments beginning on the one-month anniversary of the date of the issuance Read SEC document |
| December 07, 2022 Filed Dec 10, 2022 01:23 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 50,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001493152-22-035089 · ownership.xml · derivative · entry 12 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · Former CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-12-07 F3 · derivative.exercise_date: Options vest (and thereby become exercisable) as follows: (i) one-third on December 31, 2022, (ii) one-third on January 31, 2023, and (iii) one-third on February 28, 2023 (each such date, a "Vesting Date"), in each case, subject to the Reporting Person's continuous service as a consultant on each applicable Vesting Date. Read SEC document |
| December 01, 2022 Filed Dec 10, 2022 01:23 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Exercise / conversionRestricted Stock Units · Derivative | 250,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-035089 · ownership.xml · derivative · entry 11 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · Former CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining restricted stock units immediately vested on December 1, 2022. F2 · derivative.expiration_date: The restricted stock units were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining restricted stock units immediately vested on December 1, 2022. Read SEC document |
| December 01, 2022 Filed Dec 10, 2022 01:23 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Disposition to issuerRestricted Stock Units · Derivative | 250,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-035089 · ownership.xml · derivative · entry 10 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · Former CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires not disclosed F2 · derivative.exercise_date: The restricted stock units were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining restricted stock units immediately vested on December 1, 2022. F2 · derivative.expiration_date: The restricted stock units were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining restricted stock units immediately vested on December 1, 2022. Read SEC document |
| December 01, 2022 Filed Dec 10, 2022 01:23 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Disposition to issuerRestricted Stock Units · Derivative | 35,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-035089 · ownership.xml · derivative · entry 9 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · Former CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires not disclosed F2 · derivative.exercise_date: The restricted stock units were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining restricted stock units immediately vested on December 1, 2022. F2 · derivative.expiration_date: The restricted stock units were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining restricted stock units immediately vested on December 1, 2022. Read SEC document |
| December 01, 2022 Filed Dec 10, 2022 01:23 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Disposition to issuerOption to Purchase Common Stock · Derivative | 93,750 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001493152-22-035089 · ownership.xml · derivative · entry 8 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · Former CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,250 Underlying: Common Stock · 93,750 shares Expires not disclosed F1 · derivative.exercise_date: The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining options immediately vested and became exercisable as of December 1, 2022. F1 · derivative.expiration_date: The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining options immediately vested and became exercisable as of December 1, 2022. Read SEC document |
| December 01, 2022 Filed Dec 10, 2022 01:23 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Disposition to issuerOption to Purchase Common Stock · Derivative | 300,000 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001493152-22-035089 · ownership.xml · derivative · entry 7 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · Former CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires not disclosed F1 · derivative.exercise_date: The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining options immediately vested and became exercisable as of December 1, 2022. F1 · derivative.expiration_date: The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining options immediately vested and became exercisable as of December 1, 2022. Read SEC document |
| December 01, 2022 Filed Dec 10, 2022 01:23 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Disposition to issuerOption to Purchase Common Stock · Derivative | 500,000 | $0.00 Strike: $5.34 | $0.00 |
DisclosureSEC source: 0001493152-22-035089 · ownership.xml · derivative · entry 6 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · Former CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500,000 shares Expires not disclosed F1 · derivative.exercise_date: The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining options immediately vested and became exercisable as of December 1, 2022. F1 · derivative.expiration_date: The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining options immediately vested and became exercisable as of December 1, 2022. Read SEC document |
| December 01, 2022 Filed Dec 10, 2022 01:23 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Disposition to issuerOption to Purchase Common Stock · Derivative | 50,000 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001493152-22-035089 · ownership.xml · derivative · entry 5 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · Former CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_date: The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining options immediately vested and became exercisable as of December 1, 2022. F1 · derivative.expiration_date: The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining options immediately vested and became exercisable as of December 1, 2022. Read SEC document |
| December 01, 2022 Filed Dec 10, 2022 01:23 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Disposition to issuerOption to Purchase Common Stock · Derivative | 950,000 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0001493152-22-035089 · ownership.xml · derivative · entry 4 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · Former CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 950,000 shares Expires not disclosed F1 · derivative.exercise_date: The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining options immediately vested and became exercisable as of December 1, 2022. F1 · derivative.expiration_date: The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining options immediately vested and became exercisable as of December 1, 2022. Read SEC document |
| December 01, 2022 Filed Dec 10, 2022 01:23 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Disposition to issuerOption to Purchase Common Stock · Derivative | 45,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001493152-22-035089 · ownership.xml · derivative · entry 3 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · Former CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires not disclosed F1 · derivative.exercise_date: The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining options immediately vested and became exercisable as of December 1, 2022. F1 · derivative.expiration_date: The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining options immediately vested and became exercisable as of December 1, 2022. Read SEC document |
| December 01, 2022 Filed Dec 10, 2022 01:23 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Disposition to issuerOption to Purchase Common Stock · Derivative | 20,000 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001493152-22-035089 · ownership.xml · derivative · entry 2 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · Former CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_date: The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining options immediately vested and became exercisable as of December 1, 2022. F1 · derivative.expiration_date: The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 1, 2022. Any remaining options immediately vested and became exercisable as of December 1, 2022. Read SEC document |
| December 01, 2022 Filed Dec 10, 2022 01:23 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Exercise / conversionCommon Stock, no par value | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-035089 · ownership.xml · nonDerivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · Former CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 583,212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 20:05 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock, no par value | 40,000 | $0.96 | $38,400.00 |
DisclosureSEC source: 0001493152-22-023462 · ownership.xml · nonDerivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,212 Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 01:26 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock, no par value | 50,000 | $1.28 | $64,150.00 |
DisclosureSEC source: 0001493152-22-007205 · ownership.xml · nonDerivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,212 Read SEC document |
| March 15, 2022 Filed Mar 18, 2022 01:24 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantRestricted Stock Units · Derivative | 500,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-007202 · ownership.xml · derivative · entry 5 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2024-12-31 F5 · derivative.exercise_date: The restricted stock units will vest immediately upon the Issuer's achievement with respect to pre-defined market capitalization objectives and product-related milestones during the period beginning on January 1, 2022 and ending on December 31, 2024, subject to continuous service through the applicable vesting date. The number of restricted stock units that will vest will be determined based on the Issuer's level of achievement with respect to such pre-defined milestones. If such pre-defined milestones are not achieved at a minimum level, no vesting will occur and the restricted stock units will be cancelled. Read SEC document |
| March 15, 2022 Filed Mar 18, 2022 01:24 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantRestricted Stock Units · Derivative | 35,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-007202 · ownership.xml · derivative · entry 4 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2023-03-15 F4 · derivative.exercise_date: The restricted stock units shall vest upon the completion of one year of continuous service from the date of grant. Read SEC document |
| March 15, 2022 Filed Mar 18, 2022 01:24 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 375,000 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001493152-22-007202 · ownership.xml · derivative · entry 3 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires 2032-03-15 F3 · derivative.exercise_date: Options vest subject to the Issuer's achievement of pre-defined product-related milestones and financial performance and corporate budget objectives in 2022. The number of options that will vest will be determined based on the Issuer's level of achievement in 2022 with respect to such pre-defined objectives. If such pre-defined objectives are not achieved at a minimum level, no vesting will occur and the options will be cancelled. Options will vest in annual installments over three years from the effective date of grant, if such pre-defined objectives have been achieved in 2022, subject to continuous service through the applicable vesting date. Read SEC document |
| March 15, 2022 Filed Mar 18, 2022 01:24 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 200,000 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001493152-22-007202 · ownership.xml · derivative · entry 2 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-03-15 F2 · derivative.exercise_date: Options vest subject to the Issuer's achievement of pre-defined product development, regulatory and financial goals in 2022. 100% of the options will vest on December 31, 2023, if such pre-defined goals have been achieved in 2022, subject to continuous service through the vesting date. Read SEC document |
| March 15, 2022 Filed Mar 18, 2022 01:24 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 300,000 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001493152-22-007202 · ownership.xml · derivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2032-03-15 F1 · derivative.exercise_date: 25% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 22:05 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 40,000 | Not disclosed Strike: $1.54 | Not disclosed |
DisclosureSEC source: 0001104659-22-004058 · tm222906-1_4seq1.xml · derivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-01-11 F2 · price: Issued pursuant to the Issuer's Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer F1 · derivative.exercise_date: The options shall vest in twelve equal monthly installments beginning on the one month anniversary of the date of the issuance Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:35 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $3.22 | Not disclosed |
DisclosureSEC source: 0001104659-21-100857 · tm2124311-1_4seq1.xml · derivative · entry 1 ANDREWS RONALD ASBURY · CIK 0001299153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-08-03 F2 · price: Issued pursuant to the Issuer's Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer F1 · derivative.exercise_date: The options shall vest in twelve equal monthly installments beginning on the one month anniversary of the date of the issuance Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.